Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20525753rdf:typepubmed:Citationlld:pubmed
pubmed-article:20525753lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C1882071lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C0600558lld:lifeskim
pubmed-article:20525753lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:20525753pubmed:issue14lld:pubmed
pubmed-article:20525753pubmed:dateCreated2010-7-16lld:pubmed
pubmed-article:20525753pubmed:abstractTextComplete response to induction chemotherapy is observed in approximately 60% of patients with newly diagnosed non-M3 acute myelogenous leukemia (AML). However, no methods exist to predict with high accuracy at the individual patient level the response to standard AML induction therapy.lld:pubmed
pubmed-article:20525753pubmed:languageenglld:pubmed
pubmed-article:20525753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20525753pubmed:citationSubsetIMlld:pubmed
pubmed-article:20525753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20525753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20525753pubmed:statusMEDLINElld:pubmed
pubmed-article:20525753pubmed:monthJullld:pubmed
pubmed-article:20525753pubmed:issn1078-0432lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:MindenMark...lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:BoerE P JEPlld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:FantlWendy...lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:KornblauSteve...lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:PuttaSantoshSlld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:CesanoAlessan...lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:GaykoUrteUlld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:RosenDavid...lld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:CohenAileenAlld:pubmed
pubmed-article:20525753pubmed:authorpubmed-author:SpellmeyerDav...lld:pubmed
pubmed-article:20525753pubmed:copyrightInfoCopyright 2010 AACR.lld:pubmed
pubmed-article:20525753pubmed:issnTypePrintlld:pubmed
pubmed-article:20525753pubmed:day15lld:pubmed
pubmed-article:20525753pubmed:volume16lld:pubmed
pubmed-article:20525753pubmed:ownerNLMlld:pubmed
pubmed-article:20525753pubmed:authorsCompleteYlld:pubmed
pubmed-article:20525753pubmed:pagination3721-33lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:meshHeadingpubmed-meshheading:20525753...lld:pubmed
pubmed-article:20525753pubmed:year2010lld:pubmed
pubmed-article:20525753pubmed:articleTitleDynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.lld:pubmed
pubmed-article:20525753pubmed:affiliationDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.lld:pubmed
pubmed-article:20525753pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2322entrezgene:pubmedpubmed-article:20525753lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20525753lld:entrezgene